Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel®, SDZ ASM 981): Impact ON quality of life and health-related quality of life

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 3, 2006, Pages 248-254

  McKenna, S P ^a   Whalley, D ^a   de Prost, Y ^b   Staab, D ^c   Huels, J ^d   Paul, C F ^d,e   Assche, D ^d  

^a GALEN RESEARCH   (United Kingdom)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Lungenklinik Heckeshorn   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Mulhouse General Hospital   (France)

Author keywords

Atopic dermatitis; Child; Pimecrolimus; PIQoL AD; Qualityof life; SDZ ASM 981

Indexed keywords

CORTICOSTEROID; EMOLLIENT AGENT; PIMECROLIMUS;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INFANT; INTERNATIONAL COOPERATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL MODEL; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; CALCINEURIN; CHILD; CHILD WELFARE; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; FEMALE; HUMANS; INFANT; MALE; PEPTIDYLPROLYL ISOMERASE; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 33645999345     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01383.x     Document Type: Article

References (29)

1. Hepburn D, Yohn JJ, Weston WI. Topical steroid treatment in infants, children, and adolescents. Adv Dermatol 1994; 9: 225-255.
2. Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr 2000; 39: 1-14.
3. Stoppolino G, Prisco F, Santinelli R et al. Potential hazards of topical steroids therapy. Am J Dis Child 1983; 137: 1130-1131.
4. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931-936.
5. Fukaya M. Why do patients with atopic dermatitis refuse to apply topical corticosteroids? Dermatology 2000; 201: 242-245.
6. Van Leent EJM, Gräber M, Thurston M et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805-809.
7. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild to moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504.
8. Kapp A, Papp K, Bingham A et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in infants. J Allergy Clin Immunol 2002; 110: 277-284.
9. Whalley D, Huels J, McKenna SP, van Assche D. The benefit of pimecrolimus (Elidel®, SDZ ASM 981) on quality of life in the treatment of paediatric atopic dermatitis. Pediatrics 2002; 110: 1133-1136.
10. Queille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy: A randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-513.
11. Wahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: E2-9.
12. Meurer M, Folster-Holst R, Wozel G et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology 2002; 205: 271-277.
13. Whalley D, McKenna SP, Dewar AL et al. International development of the parents' index of quality of life in atopic dermatitis (PIQoL-AD). Qual Life Res 2005; 14: 231-241.
14. Whalley D, McKenna SP. The impact of childhood atopic dermatitis on the quality of life of the family. J Progressive Clin Insights 1999; 7: 10-11.
15. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): Initial validation and practical use. Br J Dermatol 1995; 132: 942-949.
16. Nelder JA, Wedderburn RWM. Generalized linear models. JR Stat Soc. Ser A 1972; 135: 370-384.
17. McCullagh P, Nelder JA 1989 Generalized Linear Models, 2nd edn. Chapman and Hall, London.
18. Meads DM, McKenna SP, Kahler K. The quality of life of parents of children with atopic dermatitis: Interpretation of PIQoL-AD scores. Qual Life Res 2005; 14: 2235-2245.
19. Krueger GG, Feldman SR, Camisa C et al. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-285.
20. McKenna SP, Whalley D, Doward LC. Which outcomes are important in schizophrenia trials? Int J Methods Psychiatr Res 2000; 9: S58-S67.
21. Touw CR, Kakkaart-Van Roijen L, Verboom P et al. Quality of life and clinical outcome in psoriasis using intermittent cyclosporin. Br J Dermatol 2001; 144: 967-972.
22. Wahl A, Burckhardt C, Wiklund I, Hanestad BR. The Norwegian version of the Quality of Life Scale (QOLS-N): A validation and reliability study in patients suffering from psoriasis. Scand J Caring Sci 1998; 12: 215-222.
23. Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: Physical severity, quality of life, and stigmatization. Physiol Behav 2000; 70: 567-571.
24. Barbier N, Paul C, Luger T et al. Validation of the eczema area and severity index in a population of 1550 patients with atopic dermatitis included in the pimecrolimus clinical program. Br J Dermatol 2004; 150: 96-102.
25. Lydick EG, Yawn BP. Clinical interpretation of health-related quality-of-life data. In: Staquet MJ, Hays RD, Fayers PM, eds. Quality of Life Assessment in Clinical Trials: Methods and Practice. Oxford University Press, Oxford, 1998; 299-314.
26. Charman C, Chambers C, Williams H. Measuring atopic dermatitis severity in randomized controlled clinical trials: What exactly are we measuring? J Invest Dermatol 2003; 120: 932-941.
27. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic dermatitis. Health Technol Assess 2000; 4: 1-191.
28. Kiebert G, Sorensen SV, Revicki D et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41: 151-158.
29. Lapidus CS, Kerr PE. Social impact of atopic dermatitis. Med Health R I 2001; 84: 294-295.